|Dr. Noubar B. Afeyan Ph.D.||Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board||1.12M||N/A||1963|
|Mr. Stephane Bancel||CEO & Director||3.16M||N/A||1973|
|Dr. Stephen Hoge M.D.||Pres||1.8M||165.87M||1976|
|Mr. David W. Meline||CFO & Principal Accounting Officer||1.24M||N/A||1957|
|Ms. Shannon Thyme Klinger||Chief Legal Officer & Corp. Sec.||1.76M||N/A||1971|
|Mr. Juan Andres||Chief Technical Operations & Quality Officer||1.6M||194.29M||1965|
|Dr. John V. W. Reynders||Chief Information Officer||N/A||N/A||N/A|
|Dr. Melissa J. Moore Ph.D.||Chief Scientific Officer & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Ms. Lavina Talukdar CFA||Sr. VP & Head of Investor Relations||N/A||N/A||N/A|
|Colleen Hussey||Sr. Director of Corp. Communications||N/A||N/A||N/A|
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 10; Compensation: 9.